MIP's Charlotte Kilpatrick talks to Corey Salsberg of Novartis, Ellen t’Hoen of Medicines Law and Policy, and David Rosenberg formerly of GSK to discuss how COVID-19 is reshaping IP in the life sciences.

MIP podcasts

MIP podcasts
MIP's Charlotte Kilpatrick talks to Corey Salsberg of Novartis, Ellen t’Hoen of Medicines Law and Policy, and David Rosenberg formerly of GSK to discuss how COVID-19 is reshaping IP in the life sciences.
Jun 24, 2020
MIP

Charlotte Kilpatrick, reporter at Managing IP, sat down with Corey Salsberg of Novartis, Ellen t’Hoen of Medicines Law and Policy, and David Rosenberg formerly of GSK, to discuss how COVID-19 is reshaping the IP landscape in the life sciences industries. The guests debated IP issues including access to medicine, open science, and the role patent and technology pooling can play to accelerate vaccine research.